Steffen Thirstrup, will be chairing this event:
Overview
Biosimilar medicines’ developments are maintaining their momentum, and the 2018 Biosimilars Conference programme delves into strategic discussions regarding:
• Market access and regulatory developments in the EU and globally
• National policy developments (e.g. education, incentives, government investments)
• The impact of biosimilar medicines on the competitive landscape of biological products and the sustainability of the biosimilar medicines sector
As the 5th conference of its kind, the 2018 programme will provide current updates and challenges related to biosimilar medicines. The conference will consist of plenary
sessions and multi-stakeholder panel discussions, which will allow for interaction with the audience. Participants will leave the conference with a wealth of new information
and an expanded network of contacts.
Paul Chamberlain, Biopharmaceuticals and Immunogenicity Expert, NDA Advisory Board, UK
DAY ONE | MONDAY, 22 OCTOBER
11:30 SESSION 2 – PHYSICIAN’S CHALLENGES – TREATMENT PATHWAYS
Immunogenicity – The Wrong Elephant in the Room
Click here for more details & to register